留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

诱导多潜能干细胞的研究进展

宋捷 缪朝玉

宋捷, 缪朝玉. 诱导多潜能干细胞的研究进展[J]. 药学实践与服务, 2012, 30(1): 1-3,13. doi: 10.3969/j.issn.1006-0111.2012.01.001
引用本文: 宋捷, 缪朝玉. 诱导多潜能干细胞的研究进展[J]. 药学实践与服务, 2012, 30(1): 1-3,13. doi: 10.3969/j.issn.1006-0111.2012.01.001
SONG Jie, MIAO Chao-yu. Progress on induced pluripotent stem cell[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(1): 1-3,13. doi: 10.3969/j.issn.1006-0111.2012.01.001
Citation: SONG Jie, MIAO Chao-yu. Progress on induced pluripotent stem cell[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(1): 1-3,13. doi: 10.3969/j.issn.1006-0111.2012.01.001

诱导多潜能干细胞的研究进展

doi: 10.3969/j.issn.1006-0111.2012.01.001
基金项目: 国家973计划课题(2009CB521902) ; 国家科技重大专项"重大新药创制"(2009ZX09303-002) .

Progress on induced pluripotent stem cell

  • 摘要: 诱导多潜能干细胞(IPSC)自2006年问世,就备受全球各大实验室广泛关注,成为生命科学领域新的里程碑。本篇综述旨在回顾多潜能性的研究历史,重点介绍IPSC培养技术,探讨IPSC培养技术在细胞治疗方面的应用前景。通过大量查阅国内外相关领域的综述及论著,本文归纳总结近年来IPSC领域的最新研究成果,以期为该领域后续的探索性研究提供参考。
  • [1] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors[J]. Cell, 2006, 126(4): 663.
    [2] Briggs R, King TJ. Transplantation of living nuclei from blastula cells into enucleated frogs'eggs[J]. Proc Natl Acad Sci,1952, 38(5): 455.
    [3] Miller RA, Ruddle FH. Pluripotent teratocarcinoma-thymus somatic cell hybrids[J]. Cell,1976,9(1): 45.
    [4] Xie H, Ye M, Feng R, et al. Stepwise reprogramming of B cells into macrophages[J]. Cell,2004, 117(5): 663.
    [5] Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts[J]. Cell,1987, 51(6): 987.
    [6] Ieda M, Fu JD, Delgado-Olguin P, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors[J]. Cell,2010, 142(3): 375.
    [7] Aasen T, Raya A, Barrero MJ, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes[J]. Nat Biotechnol,2008, 26(11): 1276.
    [8] Eminli S, Utikal J, Arnold K, et al. Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression[J]. Stem Cells,2008, 26(10): 2467.
    [9] Utikal J, Maherali N, Kulalert W, et al. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells[J]. J Cell Sci,2009, 122(Pt 19): 3502.
    [10] Stadtfeld M, Brennand K, Hochedlinger K. Reprogramming of pancreatic β cells into induced pluripotent stem cells[J]. Curr Biol,2008, 18(12): 890.
    [11] Sun N, Panetta NJ, Gupta DM, et al. Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells[J]. Proc Natl Acad Sci USA, 2009,106(37):15720.
    [12] Hanna J, Markoulaki S, Schorderet P, et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency[J]. Cell,2008, 133(2): 250.
    [13] Zhao XY, Li W, Lv Z, et al. iPS cells produce viable mice through tetraploid complementation[J]. Nature,2009, 461(7260): 86.
    [14] Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells[J]. Nature,2007, 448(7151): 313.
    [15] Stadtfeld M, Nagaya M, Utikal J, et al. Induced pluripotent stem cells generated without viral integration[J]. Science,2008, 322(5903): 945.
    [16] Varas F, Stadtfeld M, de Andres-Aguayo L, et al. Fibroblast-derived induced pluripotent stem cells show no common retroviral vector insertions[J]. Stem Cells,2009, 27(2): 300.
    [17] Fusaki N, Ban H, Nishiyama A, et al. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome[J]. Proc Jpn Acad,2009, 85(8): 348.
    [18] Yu J, Hu K, Smuga-Otto K, et al. Human induced pluripotent stem cells free of vector and transgene sequences[J]. Science,2009, 324(5928): 797.
    [19] Jia F, Wilson KD, Sun N, et al. A nonviral minicircle vector for deriving human iPS cells[J]. Nat Methods,2010, 7(3): 197.
    [20] Woltjen K, Michael IP, Mohseni P, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells[J]. Nature,2009, 458(7239): 766.
    [21] Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins[J]. Cell Stem Cell,2009, 4(5): 381.
    [22] Cho HJ, Lee CS, Kwon YW, et al. Induction of pluripotent stem cells from adult somatic cells by protein-based reprogramming without genetic manipulation[J]. Blood,2010, 116(3): 386.
    [23] Desponts C, Ding S. Using small molecules to improve generation of induced pluripotent stem cells from somatic cells[J]. Methods Mol Biol,2010, 636: 207.
    [24] Park IH, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells[J]. Cell,2008, 134(5): 877.
    [25] Ebert AD, Yu J, Rose FF Jr, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient[J]. Nature,2009, 457(7227): 277.
    [26] Lee G, Papapetrou EP, Kim H, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs[J]. Nature,2009,461(7262): 402.
    [27] Carvajal-Vergara X, Sevilla A, D'Souza SL, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome[J]. Nature,2010,465(7299): 808.
    [28] Hanna J, Wernig M, Markoulaki S, et al.Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin[J]. Science,2007, 318(5858): 1920.
    [29] M. Wernig, J. Pruszak, E. Hedlund, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease[J].Proc Natl Acad Sci,2008,105(15) : 5856.
    [30] D. Xu, LM. Fink, DM. Adcock, et al. Phenotypic correction ofmurine hemophilia A using an iPS cell-based therapy[J]. Proc Natl Acad Sci,2009,106(3) :808.
    [31] T.J. Nelson, S. Yamada, C. Perez-Terzic, et al. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells[J].Circ,2009,120(5) :408.
    [32] Raya A, Rodriguez-Piza I, Guenechea G et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells[J]. Nature,2009, 460(7251):53.
    [33] Couzin J. Celebration and concern over U.S. trial of embryonic stem cells[J]. Science,2009,323(5914):568.
  • [1] 林莉莉, 黄爱文, 林美钦, 方婕, 沈钦勇, 宋洪涛.  替吉奥单药或联合铂类治疗晚期非小细胞肺癌患者疗效与安全性的Meta评价 . 药学实践与服务, 2019, 37(6): 563-570. doi: 10.3969/j.issn.1006-0111.2019.06.018
    [2] 袁颖超, 廖秋菊.  炎性细胞因子与膝骨关节炎诊断及治疗的最新研究进展 . 药学实践与服务, 2018, 36(1): 9-12. doi: 10.3969/j.issn.1006-0111.2018.01.002
    [3] 靳海潮, 邢方凯, 陈涛, 吕文苓.  氨柔比星用于小细胞肺癌二线治疗的荟萃分析 . 药学实践与服务, 2017, 35(1): 82-86. doi: 10.3969/j.issn.1006-0111.2017.01.021
    [4] 郭玲玲, 仇金荣.  免疫治疗在肝细胞癌治疗中的进展 . 药学实践与服务, 2017, 35(4): 362-366. doi: 10.3969/j.issn.1006-0111.2017.04.019
    [5] 曹梦雪, 孙凡, 林厚文.  肿瘤干细胞的治疗耐受机制研究进展 . 药学实践与服务, 2017, 35(3): 193-196,247. doi: 10.3969/j.issn.1006-0111.2017.03.001
    [6] 章浩, 叶真龙, 钱其军.  降低亲和力提高HER2-CAR-T细胞治疗的安全性 . 药学实践与服务, 2016, 34(3): 261-266. doi: 10.3969/j.issn.1006-0111.2016.03.018
    [7] 黎迎, 朱春燕.  细胞共培养模型在口服药物吸收研究中的应用 . 药学实践与服务, 2015, 33(4): 289-292,327. doi: 10.3969/j.issn.1006-0111.2015.04.001
    [8] 蔡和平, 王卓.  拓扑替康标准方案与周疗方案治疗小细胞肺癌的荟萃分析 . 药学实践与服务, 2014, 32(1): 23-26,30. doi: 10.3969/j.issn.1006-0111.2014.01.006
    [9] 罗伟华, 石燕明.  穿琥宁联合更昔洛韦治疗儿童传染性单核细胞增多症疗效观察 . 药学实践与服务, 2012, 30(2): 125-127. doi: 10.3969/j.issn.1006-0111.2012.02.013
    [10] 贾国强, 杨亚青.  吉非替尼治疗非小细胞肺癌的临床疗效观察 . 药学实践与服务, 2007, (6): 399-400.
    [11] 徐嵘.  多西他赛不同给药方案治疗非小细胞肺癌的效果 . 药学实践与服务, 2007, (4): 200-202,218.
    [12] 陈清, 魏丕敬, 顾培坤, 金正钧, 周中源.  关附甲素对培养心肌细胞"缺氧缺糖"的保护作用 . 药学实践与服务, 2000, (5): 331-333.
    [13] 成冰燕, 王占元.  细胞因子与类风湿性关节炎治疗的研究进展 . 药学实践与服务, 2000, (3): 143-144.
    [14] 黄艳, 赵德修, 吕东平, 颜芳, 李佐虎.  搅拌式生物反应器悬浮培养水母雪莲细胞的研究(摘要) . 药学实践与服务, 2000, (5): 356-356.
    [15] 刘峻, 丁家宜.  富锗人参细胞的培养及含量测定 . 药学实践与服务, 2000, (5): 288-289.
    [16] 杨以真, 蔡修熙.  促肝细胞生长素治疗各型肝炎疗效的比较 . 药学实践与服务, 1999, (4): 216-218.
    [17] 张夏华, 龚守军.  促肝细胞生长素与肝生素治疗重症肝病的疗效观察 . 药学实践与服务, 1998, (5): 271-273.
    [18] 龚江宁, 董可因.  血细胞回输-治疗多发性骨髓瘤可能成功 . 药学实践与服务, 1995, (1): 7-7.
    [19] 朱蘋香.  治疗重症肝炎的新药——注射用促肝细胞生长素(HGF) . 药学实践与服务, 1993, (2): 82-84.
    [20] TSUTOMUFURUYA.  发酵罐中人参细胞培养条件的研究 . 药学实践与服务, 1984, (4): 35-36.
  • 加载中
计量
  • 文章访问数:  2524
  • HTML全文浏览量:  183
  • PDF下载量:  499
  • 被引次数: 0
出版历程
  • 收稿日期:  2011-05-06
  • 修回日期:  2011-06-08

诱导多潜能干细胞的研究进展

doi: 10.3969/j.issn.1006-0111.2012.01.001
    基金项目:  国家973计划课题(2009CB521902) ; 国家科技重大专项"重大新药创制"(2009ZX09303-002) .

摘要: 诱导多潜能干细胞(IPSC)自2006年问世,就备受全球各大实验室广泛关注,成为生命科学领域新的里程碑。本篇综述旨在回顾多潜能性的研究历史,重点介绍IPSC培养技术,探讨IPSC培养技术在细胞治疗方面的应用前景。通过大量查阅国内外相关领域的综述及论著,本文归纳总结近年来IPSC领域的最新研究成果,以期为该领域后续的探索性研究提供参考。

English Abstract

宋捷, 缪朝玉. 诱导多潜能干细胞的研究进展[J]. 药学实践与服务, 2012, 30(1): 1-3,13. doi: 10.3969/j.issn.1006-0111.2012.01.001
引用本文: 宋捷, 缪朝玉. 诱导多潜能干细胞的研究进展[J]. 药学实践与服务, 2012, 30(1): 1-3,13. doi: 10.3969/j.issn.1006-0111.2012.01.001
SONG Jie, MIAO Chao-yu. Progress on induced pluripotent stem cell[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(1): 1-3,13. doi: 10.3969/j.issn.1006-0111.2012.01.001
Citation: SONG Jie, MIAO Chao-yu. Progress on induced pluripotent stem cell[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(1): 1-3,13. doi: 10.3969/j.issn.1006-0111.2012.01.001
参考文献 (33)

目录

    /

    返回文章
    返回